Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

ment for hepatitis C patients with unmet needs, including patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and patients who have failed to respond to previous therapy.

Important Safety Information about PEGASYS

PEGASYS, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A).

Alpha interferons, including PEGASYS(R) (Peginterferon alfa-2a), may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping PEGASYS therapy (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

Use with Ribavirin. Ribavirin, including COPEGUS(R), may cause birth defects and/or death of the fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with ribavirin therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

PEGASYS is contraindicated in patients with hypersensitivity to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; class B and C) in cirrhotic CHC monoinfected patients before or during tre
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... -- Market research firm Kalorama information says that 2014 will ... the medical device industry.  The firm thinks the $360 ... 3% growth this year, which led firms to look ... and entrance by acquisition into new competitive zones.  The ... The Global Market for Medical Devices, 5 th ...
(Date:11/21/2014)... /CNW Telbec/ - KLOX Technologies Inc. ("KLOX" or the ... Todd Martensen has been hired ... of Chief Commercial Officer, to oversee KLOX,s commercial launch ... for the treatment of chronic and other hard-to-heal wounds, ... in Europe . Mr. Martensen, a ...
(Date:11/21/2014)... Inc. (NASDAQ: DEPO ) today announced that it will ... Conference in New York City . ... am EST (5:00 am PST) on Tuesday December 2, 2014.  The ... the Investor Relations page of the Depomed website at www.depomed.com ... days on the company,s website. About Depomed ...
Breaking Medicine Technology:Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2
... Pharmaceuticals, Inc. (NASDAQ: SVNT ) today reported financial ... ended the quarter with $268.0 million in cash and short-term ... primarily due to the issuance and sale of $230 million ... of 2011, the Company had a net loss of $13.5 ...
... 5, 2011 Delcath Systems, Inc. (NASDAQ: DCTH ... Annual JMP Securities Research Conference on Wednesday, May ... David McDonald, Chief Financial Officer, will provide an overview of ... Attendance at this conference is by invitation only. Delcath ...
Cached Medicine Technology:Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 2Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 3Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 4Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 5Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 6Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 7Delcath to Present at the JMP Securities Research Conference 2Delcath to Present at the JMP Securities Research Conference 3
(Date:11/22/2014)... wide variety and complexity of foods served at holiday ... allergies, an expert warns. "Every person is different ... that it can be really difficult to avoid all ... allergy and clinical immunology at Wake Forest Baptist Medical ... you know you have food allergies, caution should overrule ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Recently, UWDress.com ... wedding guest dresses . In addition, the company ... products. , As a leading online supplier of ... of beautiful outfits. The unusual best wedding guest gowns ... Besides the amazing designs, this new selection is famous ...
(Date:11/22/2014)... Developers and plugin specialist of Final Cut Pro X ... bringing the impossible to FCPX from Pixel Film ... files to FCPX enabling 3d Model editing,” said Christina Austin, ... and armature, FCPX 3D Model is a definite game changer.” ... Pro X users to upload and control 3D objects in ...
(Date:11/22/2014)... (HealthDay News) -- Many young people consider hookahs a ... study finds fumes from the water pipes contain the ... increased risk for leukemia in prior research, according to ... Cancer Epidemiology, Biomarkers & Prevention . "In ... not a safe alternative to smoking other forms of ...
(Date:11/21/2014)... New Haven, CT (PRWEB) November 21, 2014 ... has added a veteran radio industry sales professional to ... Radio Disney, brings 30 years of leadership and sales ... Detroit office and assume the title of Director of ... Strategy and Development, Robert O’Mara. , Heinemann will handle ...
Breaking Medicine News(10 mins):Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:Pixel Film Studios released FCPX 3D Model plugin Exclusively for Final Cut Pro X 2Health News:Hookahs Deliver Toxic Benzene in Every Puff, Study Shows 2Health News:Radio Industry Veteran Joins CRN International’s Sales Organization in Detroit 2
... and other factors influence the way// individuals perceive loudness ... report. ,Tinnitus, a ringing, buzzing or whistling sound ... can be acute or chronic, constant or intermittent. Tinnitus ... unknown origin. According to background information in the article, ...
... treatment for new born babies who develop jaundice soon ... researchers say that this increases the likelihood of moles ... life. Such moles are termed melanocytic naevi in medical ... ,like melanoma ,are linked to naevi, the researchers warn ...
... Paris: To ascertain the exact reason that led to the ... France//, officials are conducting detailed tests, though preliminary investigations have ... by the ministry, the death of the birds was sudden, ... keeping healthy. The owner of the farm is pretty ...
... Gov. Ed Rendell will announce a health care reform plan ... to millions of Pennsylvanians who lack coverage. Governor added that ... ,The plan, which was under development for months, ... supported by Mr. Rendell. ,Moreover, Mr. Rendell ...
... surgical procedures may be more likely to develop pneumonia ... those without HIV, according to a report in the ... JAMA/Archives journals. In addition, HIV patients with a preoperative ... the blood) greater than 30,000 per milliliter appear to ...
... states of India migrate to the industrialized regions in India's ... AIDS.// Bihari migrants are estimated to range from two million ... security guards or domestic servants in India's big cities. ... doing," Srivastava, a Bihari aged 48, told Reporters in Patna, ...
Cached Medicine News:Health News:Clinical Factors of Tinnitus Influence Perceived Loudness and Annoyance 2Health News:HIV Patients Have Increased Risk of Pneumonia, Death Following Surgery 2Health News:Poverty Fuels HIV In Poor Indian States 2
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Medicine Products: